LRRK2 and Parkinson disease: Nonetheless, the incomplete penetrance (e.g. G2019S PD: 28–74% at 59–79 years [34]) alongside the considerable variation in neuropathology within carriers of the same LRRK2 risk variants [18, 45–47] emphasizes that additional unknown factors shape the disease phenotype.